The Company had total cash resources of CHF 108.5 million, composed of CHF 27.7 million in cash and cash equivalents and CHF 80.7 million in short-term financial assets. The Company’s cash balance is expected to provide sufficient capital resources to the end of Q3 2027, excluding potential milestone payments.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACIU:
- AC Immune appoints Mummery as Chair of Clinical Advisory Board
- AC Immune’s ACI-24.060 Study: A Potential Game-Changer in Alzheimer’s Treatment
- AC Immune’s Innovative PET Tracer Study: A Potential Game-Changer for Neurodegenerative Diagnostics
- AC Immune’s Innovative PET Radioligand Study: A Potential Game-Changer in Neurodegenerative Diagnostics
- AC Immune SA: Pioneering Innovations in Neurodegenerative Disease Treatment and Diagnostics